

Synthetic Biology Ownership and Innovation: Industry and other Perspectives

Lionel Clarke

UK Synthetic Biology Leadership Council




IP-related responses from UK Synbio Special Interest Group June 2013

Easier process for licensing publically funded IP from universities	6
Not so many random, unsubstantiated IP filings	1
safeguarding IP rights internationally (e.g vs BRIC)	1
barriers within a multinational to exploiting external proprietary enabling technologies	1
empowering inventors within university where institution more reluctant	4
time pressure on academics to publish vs patent	1
standards and open-access issues	1
need for guidance - complexity of IP law	1




Routes from Idea to Market



To commercialise an idea, many innovations and most investment occurs downstream. Costs and Risk increase along the chain, but value only captured upon delivery to market



Intellectual Property and Financial value



Some closing observations

- There is not a 'single industry' but 'many industries' – no single best point at which to switch from 'open' to 'closed'.
- There is often a disconnect between the point in time at which an original concept is conceived (and IP filed) and where most value is accumulated in the value chain.
- SynBio as a field is developing rapidly – a potentially patentable idea or concept may lend itself towards a clearly defined output or to a range of outputs, many of which may not be recognised at the time of the original invention.
Avoid unintentionally impeding future benefits of innovation.



Thank You

